Latest Breaking News On - Tactic 2 trial - Page 1 : comparemela.com

Benjamin L. Schlechter, MD, discusses the future implications of TAC01-HER2 therapy in patients with HER2-positive solid tumors.

Benjaminl schlechterDana farber cancer instituteHarvard medical schoolTac01 her2 therapyPatients with her2 positive solid tumorsTactic 2 trial